2024年6月20日,科睿唯安(Clarivate Analytics,原汤森路透知识产权与科技事业部)发布了一年一度的期刊引证报告(Journal Citation Reports)。AME旗下杂志Translational Lung Cancer Research(中文名为《肺癌转化研究》杂志,简称TLCR杂志,图2)获得最新影响因子(Impact Factor,简称IF):4分。 图1TLCR杂志的引证报告 图2TLCR...
2019年6月20日,在科睿唯安发布的2019年Journal Citation Reports(期刊引证报告,简称JCR)中,AME旗下杂志Translational Lung Cancer Research (中文名为《肺癌转化研究》杂志,简称TLCR杂志,图1)迎来了首个影响因子(Impact Factor):4.806。 图1. TLCR 2018年10月11日,科睿唯安宣布TLCR杂志被SCIE收录,TLCR杂志成为AME旗...
2022年6月28日,科睿唯安(Clarivate Analytics,原汤森路透知识产权与科技事业部)发布了一年一度的期刊引证报告(Journal Citation Reports)。AME旗下杂志Translational Lung Cancer Research(中文名为《肺癌转化研究》杂志,简称TLCR杂志,图1)获得最...
JCR 影响因子(Impact factor), 5年期影响因子, 即年指数(Immediacy Index), 论文数量, 半衰期, 特征因子(Eigenfactor), 论文影响分值 [科研必备] 专业SCI论文修改服务: ★先修改后付款;☆语言问题免费重修;★24-72小时交稿; ☆正规财务发票;★一分钟下单;☆365日不间断服务 期刊全名 lung cancer 期刊简称 LUNG...
Lung cancer is the leading cause of cancer-associated mortality worldwide1. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx s
Lung Cancer杂志是一本医学-呼吸系统应用杂志。是一本享有盛誉的顶级学术杂志,由Elsevier Ireland Ltd出版,该期刊创刊于1985年,出版周期为Monthly,始终保持着高质量和高水平的学术内容。在中科院分区表2023年12月升级版中,被归类为大类学科分区2区,显示出其卓越的学术水平和影响力。ISSN...
Lung Cancer Supports open access 9.4CiteScore 4.5Impact Factor Articles & Issues About Publish Order journal Menu Articles & Issues Latest issue All issues Articles in press Special issues and article collections Linked datasets Sign in to set up alerts RSS About Publish Order journal...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated wit
【2hr】MET targeted therapy for lung cancer: clinical development and future directions 包量 机译MET靶向治疗肺癌:临床发展和未来方向 作者:Yan FengPatrick C Ma 刊名:Lung Cancer: Targets and Therapy 2012年第-1期 摘要:MET, the receptor for hepatocyte growth factor, has been identified a...
lung cancer compared to never smokers (Govindan 2012). Moreover, comparisons of the 2 groups showed marked differences in the profile of mutations. For instance, overexpression of epidermal growth factor receptor (EGFR) is more common in lung cancer among never smokers (Pallis 2013a; Larsen ...